Description
AesPLLA Poly-L-Lactic Acid Collagen Stimulator Injectable for Facial Volume Restoration and Wrinkle Correction
aesPLLA® Poly-L-Lactic Acid (PLLA) Collagen Stimulator is a biodegradable injectable collagen-stimulating device designed to support gradual facial volume restoration through neocollagenesis rather than immediate volumisation. The product contains poly-L-lactic acid (PLLA), a synthetic biocompatible polymer that has been extensively studied in aesthetic medicine for its ability to stimulate fibroblast activity and promote endogenous collagen production over time.
Unlike conventional hyaluronic acid fillers that primarily provide immediate space-occupying volume, aesPLLA® acts as a biostimulatory treatment. Following administration and reconstitution according to manufacturer instructions, PLLA microparticles gradually trigger a controlled tissue response that may lead to progressive collagen deposition and structural support within treated tissues.
aesPLLA® is intended for use by qualified medical professionals and is commonly selected for patients seeking gradual correction of age-related volume loss and skin laxity. Treatment outcomes develop progressively over several weeks and months following treatment.
What aesPLLA® Is Similar To
aesPLLA® belongs to the category of collagen-stimulating injectables and is commonly compared with products such as Sculptra® and Lanluma®. All three products utilise poly-L-lactic acid as their primary active component and are intended to stimulate endogenous collagen production rather than provide immediate volumisation through hyaluronic acid implantation.
Compared with traditional HA fillers such as Juvederm® Voluma or Restylane® Lyft, PLLA-based products typically deliver gradual improvements over multiple treatment sessions. Results often emerge progressively as collagen remodelling occurs following administration. Product selection depends on treatment goals, patient anatomy, desired correction pattern, practitioner preference, and treatment planning considerations.
Patients seeking immediate correction may be better suited to conventional HA fillers, while collagen stimulators are often selected where progressive tissue support and collagen induction are desired.
This comparison is provided for clinical orientation only and does not imply interchangeability.
Treatment Areas / Indications
Publicly available manufacturer and distributor information indicates that aesPLLA® may be used in areas associated with age-related volume loss and collagen depletion.
Commonly referenced treatment areas include:
- Face
- Cheeks
- Midface
- Temples
- Jawline
- Lower face
- Areas affected by age-related volume deficiency
Additional treatment indications should be verified against the current manufacturer IFU.
Usage / Administration (IFU-Only Section)
The following information should be verified against the latest manufacturer Instructions for Use (IFU).
- Reconstitution requirements: Product requires reconstitution prior to administration according to manufacturer instructions.
- Professional-use statement: aesPLLA® should be administered exclusively by qualified healthcare professionals using aseptic technique and appropriate injection training.
Some practitioners employ proprietary dilution or treatment protocols; these methods are not included in the manufacturer’s official IFU unless specifically stated by the manufacturer.
Ingredient List
Active Ingredient
- Poly-L-Lactic Acid (PLLA) – 365 mg per vial
Additional Components
- Sodium carboxymethylcellulose (CMC)
- Mannitol
Hyaluronic Acid Content
- Not applicable (product does not contain hyaluronic acid)
Lidocaine Content
- Not provided by manufacturer
Presentation & Longevity
Presentation
- 1 × vial
- 365 mg Poly-L-Lactic Acid formulation
- Sterile professional-use product requiring reconstitution before treatment
Shelf Life
- Not provided by manufacturer in publicly accessible documentation.
Longevity
PLLA-based collagen stimulators are designed to stimulate collagen production gradually over time. Individual treatment outcomes vary according to patient characteristics, treatment protocol, practitioner technique, and metabolic factors.
Treatment duration range: Not provided by manufacturer.
Safety Notes / Contraindications
According to standard PLLA product precautions and publicly available manufacturer information, treatment should not be performed in:
- Patients with known hypersensitivity to any product component.
- Areas affected by active infection, inflammation, or skin disease.
- Patients where injectable aesthetic treatments are contraindicated according to medical assessment.
Additional precautions include:
- Product should only be administered by appropriately trained healthcare professionals.
- Proper reconstitution and injection technique are important for safe administration.
- Patients should undergo full clinical evaluation prior to treatment.
Regulatory Status
- CE-marked medical device according to publicly available European distributor information.
- Intended for professional aesthetic medical use.
Regulatory classification not specified in public documentation; verify on the product packaging or manufacturer IFU before purchase and use.
FAQ
1. What is aesPLLA® and how does it work?
aesPLLA® is a collagen stimulator containing poly-L-lactic acid (PLLA). After administration, PLLA microparticles act as a scaffold that encourages the body’s natural collagen production processes. Unlike conventional fillers that create immediate volume, the product is designed to support gradual tissue remodelling through collagen induction over time.
2. Is aesPLLA® a dermal filler?
aesPLLA® is classified primarily as a collagen stimulator rather than a traditional hyaluronic acid dermal filler. While it can contribute to volume restoration, its mechanism relies on neocollagenesis rather than direct volumisation from implanted HA gel. This distinction influences both treatment planning and expected timelines for visible results.
3. How quickly are results seen after treatment?
PLLA treatments typically produce gradual improvements rather than immediate correction. Visible changes generally develop over several weeks as collagen production progresses within the treated tissues. Individual response varies according to age, metabolism, treatment area, and practitioner protocol.
4. Does aesPLLA® contain hyaluronic acid?
No. aesPLLA® is based on poly-L-lactic acid technology and does not contain hyaluronic acid. Its primary purpose is collagen stimulation rather than direct hydration or immediate volumisation commonly associated with HA fillers.
5. How does aesPLLA® compare with Sculptra®?
Both aesPLLA® and Sculptra® belong to the PLLA collagen stimulator category and work through similar biological mechanisms involving collagen induction. Differences may exist in formulation characteristics, reconstitution protocols, treatment planning approaches, and manufacturer-specific guidance. Product selection should always be determined by practitioner assessment and treatment objectives.
